# High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant

> **NCT00637767** · PHASE2 · TERMINATED · sponsor: **University of Southampton** · enrollment: 25 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** melphalan
- **PROCEDURE:** autologous hematopoietic stem cell transplantation
- **RADIATION:** yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183

## Key facts

- **NCT ID:** NCT00637767
- **Lead sponsor:** University of Southampton
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12-01
- **Primary completion:** 2013-10-31
- **Final completion:** 2013-10-31
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Low recruitment
- **Last updated:** 2020-12-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00637767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00637767, "High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00637767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*